MTNB (Matinas BioPharma Holdings) Moat Score: 3/10 (As of Jul. 01, 2026)


MTNB Matinas BioPharma Holdings Inc MTNB
31 GF Score
Price $0.63
! 3 Warning Signs
View Full Analysis

What is Matinas BioPharma Holdings Moat Score?

Matinas BioPharma Holdings MTNB +2.94% 31 Moat Score is 3 as of Jul. 01, 2026. GuruFocus rates MTNB with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,400 Biotechnology companies, Matinas BioPharma Holdings ranks better than 75.5% on this metric.

Matinas BioPharma Holdings has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Matinas BioPharma Holdings has No Moat: Matinas BioPharma Holdings Inc has very weak competitive advantages. It lacks market leadership, network effects, and customer loyalty. The company operates in a competitive biotech industry with no significant intellectual property or cost advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Matinas BioPharma Holdings might have No Moat - Very weak/transient advantages.

Matinas BioPharma Holdings  (AMEX:MTNB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Matinas BioPharma Holdings Moat Score Related Terms

MTNB vs SXTP, ARTL, GLMD: Moat Score Comparison

For the Biotechnology subindustry, Matinas BioPharma Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Matinas BioPharma Holdings Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's Moat Score falls into.


MTNB
31GF Score
Matinas BioPharma Holdings Inc MTNB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Matinas BioPharma Holdings (MTNB) has a Moat Score of 3 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Matinas BioPharma Holdings ranks #343 out of 1400 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Matinas BioPharma Holdings' Moat Score too high?
Matinas BioPharma Holdings' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Matinas BioPharma Holdings' value of 3 is 50% above this industry median. Based on the distribution chart, Matinas BioPharma Holdings ranks #343 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Matinas BioPharma Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Matinas BioPharma Holdings' Moat Score compare to SXTP and ARTL?
According to the Biotechnology industry distribution chart, Matinas BioPharma Holdings ranks #343 out of 1400 companies for Moat Score. This places Matinas BioPharma Holdings in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Matinas BioPharma Holdings' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Matinas BioPharma Holdings's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Matinas BioPharma Holdings's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Matinas BioPharma Holdings stock overvalued right now?
Matinas BioPharma Holdings (MTNB) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Matinas BioPharma Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Matinas BioPharma Holdings (MTNB), the current Moat Score is 3 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Matinas BioPharma Holdings Business Description

Address 1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
31GF Score

Get the complete analysis for MTNB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.63
Price